Literature DB >> 14689079

[Drug interactions. Mechanisms and clinical relevance].

U Klotz1, W Beil, C Gleiter, B Drewelow, E Garbe, A Gillessen, E Mutschler.   

Abstract

During the last few years 3 important drugs (terfenadine, mibefradil, cisapride) had to been withdrawn from the market because of serious drug-drug interactions. Polypragmacy, not only in advanced age, is often applied. Consequently the possibility of pharmacokinetic and/or pharmacodynamic drug interactions has always to be taken into account which can cause adverse effects, therapeutic failures, hospital admissions and extra costs. Clinically relevant interactions can be observed especially on the level of drug metabolism and transport. Both pharmacokinetic processes can be induced or inhibited by numerous agents. Taking proton pump inhibitors as an example it could be shown that the various compounds can differ in their interaction potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689079     DOI: 10.1007/s00108-003-1045-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

Authors:  J W Ko; N Sukhova; D Thacker; P Chen; D A Flockhart
Journal:  Drug Metab Dispos       Date:  1997-07       Impact factor: 3.922

Review 2.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  Drug-drug interactions among elderly patients hospitalized for drug toxicity.

Authors:  David N Juurlink; Muhammad Mamdani; Alexander Kopp; Andreas Laupacis; Donald A Redelmeier
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

4.  P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.

Authors:  C Pauli-Magnus; T Mürdter; A Godel; T Mettang; M Eichelbaum; U Klotz; M F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-03       Impact factor: 3.000

5.  Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

Authors:  Jiunn H Lin
Journal:  Adv Drug Deliv Rev       Date:  2003-01-21       Impact factor: 15.470

6.  Effect of omeprazole on the pharmacokinetics of itraconazole.

Authors:  S Jaruratanasirikul; S Sriwiriyajan
Journal:  Eur J Clin Pharmacol       Date:  1998-04       Impact factor: 2.953

7.  Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture.

Authors:  R Curi-Pedrosa; M Daujat; L Pichard; J C Ourlin; P Clair; L Gervot; P Lesca; J Domergue; H Joyeux; G Fourtanier
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

8.  Omeprazole treatment does not affect the metabolism of caffeine.

Authors:  T Andersson; R Bergstrand; C Cederberg; S Eriksson; P O Lagerström; I Skånberg
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

9.  Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Authors:  Sebastian Schneeweiss; Joerg Hasford; Martin Göttler; Annemarie Hoffmann; Ann-Kathrin Riethling; Jerry Avorn
Journal:  Eur J Clin Pharmacol       Date:  2002-06-12       Impact factor: 2.953

10.  Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.

Authors:  K L Rost; H Brösicke; J Brockmöller; M Scheffler; H Helge; I Roots
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

View more
  3 in total

Review 1.  [Drug interactions in geriatric medicine].

Authors:  Angela Storka; Johannes Pleiner
Journal:  Wien Med Wochenschr       Date:  2009

2.  [Reflux esophagitis].

Authors:  I Schiefke; J Mössner; K Caca
Journal:  Internist (Berl)       Date:  2005-03       Impact factor: 0.743

3.  Improvement in the handling of drug-drug interactions.

Authors:  Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.